The immune response in HPV(+) oropharyngeal cancer

Although human papillomavirus (HPV)(+) oropharyngeal cancers often present with metastasis, most patients have excellent long-term survival. The reason underlying such an apparent contradiction remains unclear, but we have recently demonstrated that the improved survival of HPV(+) oropharyngeal canc...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Emma V, Ottensmeier, Christian H, Thomas, Gareth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916354/
https://www.ncbi.nlm.nih.gov/pubmed/24575385
http://dx.doi.org/10.4161/onci.27254
_version_ 1782302698185424896
author King, Emma V
Ottensmeier, Christian H
Thomas, Gareth J
author_facet King, Emma V
Ottensmeier, Christian H
Thomas, Gareth J
author_sort King, Emma V
collection PubMed
description Although human papillomavirus (HPV)(+) oropharyngeal cancers often present with metastasis, most patients have excellent long-term survival. The reason underlying such an apparent contradiction remains unclear, but we have recently demonstrated that the improved survival of HPV(+) oropharyngeal cancer patients has an immunological component, as the levels of tumor-infiltrating lymphocytes (TILs) can be used to stratify HPV(+) patients into high-risk and low-risk groups.
format Online
Article
Text
id pubmed-3916354
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39163542014-02-26 The immune response in HPV(+) oropharyngeal cancer King, Emma V Ottensmeier, Christian H Thomas, Gareth J Oncoimmunology Author's View Although human papillomavirus (HPV)(+) oropharyngeal cancers often present with metastasis, most patients have excellent long-term survival. The reason underlying such an apparent contradiction remains unclear, but we have recently demonstrated that the improved survival of HPV(+) oropharyngeal cancer patients has an immunological component, as the levels of tumor-infiltrating lymphocytes (TILs) can be used to stratify HPV(+) patients into high-risk and low-risk groups. Landes Bioscience 2014-01-01 /pmc/articles/PMC3916354/ /pubmed/24575385 http://dx.doi.org/10.4161/onci.27254 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
King, Emma V
Ottensmeier, Christian H
Thomas, Gareth J
The immune response in HPV(+) oropharyngeal cancer
title The immune response in HPV(+) oropharyngeal cancer
title_full The immune response in HPV(+) oropharyngeal cancer
title_fullStr The immune response in HPV(+) oropharyngeal cancer
title_full_unstemmed The immune response in HPV(+) oropharyngeal cancer
title_short The immune response in HPV(+) oropharyngeal cancer
title_sort immune response in hpv(+) oropharyngeal cancer
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916354/
https://www.ncbi.nlm.nih.gov/pubmed/24575385
http://dx.doi.org/10.4161/onci.27254
work_keys_str_mv AT kingemmav theimmuneresponseinhpvoropharyngealcancer
AT ottensmeierchristianh theimmuneresponseinhpvoropharyngealcancer
AT thomasgarethj theimmuneresponseinhpvoropharyngealcancer
AT kingemmav immuneresponseinhpvoropharyngealcancer
AT ottensmeierchristianh immuneresponseinhpvoropharyngealcancer
AT thomasgarethj immuneresponseinhpvoropharyngealcancer

Ejemplares similares